Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe
ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new...
-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets --
ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control...
TW's Take: excellent news for FEMY. If the company executes, the financing risk is really off the table here. Clear runway in front of the company now.
Successful completion of first trial phase enables continued pivotal trial of FemBloc, the...
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access --
ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and...
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination
ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more...
TW's Take: eventually sales pick up and they can stop dilution. Been a painful trip down.
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health...
-- Continued Progress on Regulatory Approvals and
Global Commercialization of Fertility Portfolio --
ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced...
TW's Take: excellent news for FEMY. Their products are highly innovative and completely ignored by the markets to date. As word spreads, the stock should benefit greatly.
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability...
TW's Take: while not unexpected, this is an important milestone for the company. With the Trump administration more focused on issues around women's health, this could help speed things up in the US as well.
--European CE mark approval of...
TW's Take: sales growth has disappointed to date but increased acceptance at facilities like this one should eventually lead to the acceleration in sales that investors are expecting.
-- Femasys continues to expand access and market share for its first-line...
TW's Take: the products are great it's just bridging the divide until revenues really kick in that has been the issue for FEMY. Hopefully this round of financing can do that.
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc....
TW's Take: ramp is happening albeit we had hoped for stronger guidance.
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain --
ATLANTA, March 27, 2025 (GLOBE NEWSWIRE)...